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Summary: In a large phase III randomised-controlled trial among HIV-infected persons 
presenting with late stage HIV-infection , we showed that  cryptococcal meningitis screening 
and community-based early adherence support was a highly cost-effective strategy in 
reducing all-cause mortality.  
 
ABSTRACT 
 
Background  
A randomised trial demonstrated that among late-stage HIV-infected patients initiating ART, 
screening serum for cryptococcal antigen (CrAg) combined with community -based 
adherence support reduced all-cause mortality by 28%, compared with standard clinic-
based care. Here, we present the cost-effectiveness estimates.  
 
Methods  
HIV-infected adults with CD4 count<200 cells/ l were randomised individually to either CrAg 
screening plus 4-weekly home visits conducted by lay-workers to provide adherence support 
or to standard clinic-based care in Dar es Salaam and in Lusaka. Data on individual resource 
use and health outcomes were collected from all participants.  
 
Unit costs were obtained in Dar es Salaam. The primary economic outcome was health 
service care cost per life year saved as the incremental cost-effectiveness ratio (ICER), based 
on 2017 US$. Regression models were used to estimate adjusted mean incremental costs 
and death rates. Life years saved were estimated based on reported comparable survival 
data. We used non-parametric bootstrapping to assess uncertainties, and univariate 
deterministic sensitivity analysis to examine the impact of individual parameters on the 
ICER.  
 
Results  
1,001 and 998 participants from the intervention and standard arms were enrolled 
respectively. The annual mean costs per participant in the intervention arm was US$ 339  
(95% confidence interval (CI): 331  – 347 ), resulting in an incremental cost of the 
intervention of US$ 77  (95% CI: 66 - 88). The incremental cost was similar  when analysis 
was restricted to persons with CD4 count <100 cells / l.  
 
The ICER for the intervention versus standard care, per life year saved, was US$  70 (95%CI: 
43 -211) for all participants with CD4 count up to 200 cells/ l and US$91 (49–443) among 
those with CD4 counts <100 cells / l. The cost-effectiveness results were most sensitive to 
mortality estimates. 
 
Conclusions  
Screening for cryptococcal antigen in patients with CD4 count up to 200 cells/ l, combined 
with a short period of home-based adherence support, is cost-effective in resource-limited 
settings.  
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BACKGROUND 
 
Antiretroviral therapy (ART) is available widely in Africa, but HIV-associated mortality 
remains high, particularly during the first few months that patients come into care [1-4]. 
Most of the early mortality is attributed to tuberculosis and cryptococcal meningitis [5-8].   
We recently conducted a large randomised-controlled trial among HIV-infected patients 
starting ART with with CD4 count <200 cells / l in Dar es Salaam, Tanzania and in Lusaka, 
Zambia, known as the REMSTART trial [9]. The intervention comprised i) screening for 
cryptococcal infection using serum cryptococcal antigen (CrAg) combined with pre-emptive 
fluconazole therapy for patients testing CrAg positive; and  ii) weekly home visits for the first 
4 weeks for patients on ART by trained lay workers to provide adherence support. This 
package was compared with standard care. Participants in both arms were screened for 
tuberculosis with sputum Xpert irrespective of symptoms and all were initiated rapidly on 
ART within a median of 14 days (interquatile range of 9-20 days) following presentation. At 
12 months of follow-up, all cause mortality was 28% (95% confidence interval (CI): 11% - 
43%) lower in the intervention arm compared to that in the standard care arm.  
 
Findings from the trial informed the WHO guidelines on the management of late-stage HIV-
infection in Africa [9]. However, coverage of CrAg screening remains low [10]  despite the 
WHO recommendation and low cost of a CrAg test, and very few settings offer repeated 
initial adherence support to patients with advance disease starting antiretroviral therapy. To 
inform policy and practice considerations, we conducted a cost-effectiveness analysis of 
CrAg screening and early adherence support compared with standard care using data from 
the REMSTART trial.  
 
 
METHODS 
 
Study design and participants  
 
The REMSTART trial results have been published [9, 11]. In brief, the participants were HIV-
infected adults presenting for care at routine health services between February 2012 and 
September 2013. 1001 were randomised to the intervention arm and 998 to standard care.   
In the intervention arm, the participants were screened for serum CrAg using lateral flow 
tests (IMMY, Norman, OK, USA) and promptly started on fluconazole (800 mg per day for 2 
weeks followed by 400 mg per day for 8 weeks) if they were CrAg positive. In addition, they 
received up to 4 weekly home visits by trained lay-workers during the first 4 weeks of 
starting ART. The primary endpoint was all-cause mortality at 12 months of follow-up. 
 
The economic evaluation was nested within the trial and done from a health care provider’s 
perspective [11, 12]. The resource use and related costs were collected from all participants. 
Unit costs were obtained from Dar es Salaam 10. We assessed the incremental cost-
effectiveness ratio (ICER) of the intervention versus standard treatment for the duration of 
the follow up period.  It was assumed that the illness pathways of the control and treatment 
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group would be equivalent thereafter and that the incremental impact of the intervention 
on morbidity would thus be negligible.  
 
Measurement of costs and outcomes 
 
Health cost data were collected in 2012 and capital costs were discounted using a discount 
rate of 7.8% equal to the 2-year Tanzanian government bond at the time of calculation, June 
2014 [13]. All costs were converted to 2017 US$ using a gross domestic product deflator and 
an exchange rate [14].  
 
Life years gained was used as the primary outcome measure.  As the morbidity effects of the 
intervention relative to the mortality effect, are likely to be minimal in this context, these 
can be used to approximate DALYs saved.  In order to estimate life years gained, we 
computed the difference in the annual probability of death between the intervention and 
control arms (rather than the incidence rates of death per person-years of observation used 
in the main paper [9]), and multiplied this by the related life expectancy. We assumed that 
average life expectancy was 24.0 years (95% CI: 22.2 – 25.8 ) for all patients with CD4 count 
up to 200 cells/ l, 18.7 years (95% CI: 17.2 – 20.3) for patients with CD4 cell count <100 cells 
/ l, and for patients with CD4 cell count <50 cells / l based on data for similar patients on 
ART [15].  
 
Statistical analyses  
 
Differences between the intervention and standard care in costs and mortality were 
estimated using seemingly unrelated regression equations to account for the correlation 
between costs and mortality [16]. The models included baseline body weight, baseline CD4 
count and baseline hemoglobin levels which were shown to predict mortality at 12 months. 
ICERs were estimated by dividing mean incremental costs by the mean number of life years 
saved, and cost-effectiveness planes and acceptability curves were plotted. Confidence 
intervals were obtained using non-parametric bootstrapping.  
 
Univariate deterministic sensitivity analyses were done to assess the impact of parameter 
uncertainty on the ICER and were presented as a standard tornado sensitivity graph. The 
parameter ranges used for sensitivity analysis were based on 95% confidence intervals 
calculated from the REMSTART data and the observed life expectancy confidence intervals 
[15]. We conducted a secondary analysis, restricting to participants with CD4 count level 
<100 cells / l, as CrAg screening is recommended for this HIV-infected population [17].  
 
Ethics statement 
 
The study was approved by the ethics committee of the London School of Hygiene & 
Tropical Medicine, the Ethics and Research Science committee in Zambia, and the National 
Health Research Ethics Sub-Committee in Tanzania.  
 
Role of the funding source 
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The funders of the study had no role in study design, data collection, data analysis, data 
interpretation or writing of the report. The corresponding author had full access to all the 
data in the study and had the final responsibility for the decision to submit for publication. 
 
 
RESULTS 
 
Table 1 presents the unit costs for the different components of antiretroviral treatment 
(ART) services and the quantity of resources utilised by participants. The mean cost of a 
home visit was almost 3 times higher than the cost of the participant visiting the health 
facility. The unit price for the home visit comprised monthly salary for the lay worker, 
training, communication and transport allowance. CrAg testing was about a quarter of the 
cost of either a CD4  count or Xpert test.  
 
The total mean costs per patient did not differ by CD4 count category for either arm (Table 
2). The intervention resulted in approximately 30% (95% CI: 25 – 35) increase in the cost per 
patient, and resulted in an incremental cost effectiveness ratio of US$ 70 (95% CI: 43, 211) 
for participants with CD4 <200 cells / l.  
 
The absolute reductions in death rates between the intervention and standard care did not 
differ significantly by CD4 count category (Table 2).  The mortality risk ratio of the 
intervention (134/1001 deaths) versus standard care (180/998 deaths) was 0.74 (95% CI: 
0.60 - 0.91) among all participants with CD4 <200 cells / l. For participants with CD4 count 
<100 cells / l, this risk ratio was 0.77 (95% CI: 0.62 – 0.96) (114/724 versus 144/707 deaths).  
 
Cost-effectiveness, uncertainty and sensitivity analyses  
 
The intervention was more costly but more effective than the standard care (Figure 1). 
Average incremental cost-effectiveness ratios increased somewhat with decreasing CD4 cell 
count category (Table 2). 
 
The probability that the intervention is cost effective when compared with the standard 
care if the decision-makers are willing to pay between US$ 100 and US$ 150 for an 
additional life year saved varies between 84% and 95% in persons with CD4 count <200 cells 
/ l and between 62% and 82% in persons with CD4 count <100 cells /  (Figure 2).  
 
In sensitivity analyses, the most influential parameter of the incremental cost-effectiveness 
ratio was the mortality rate (Figure 3). If the annual mortality in the intervention arm is as 
low as 12%, then the incremental cost-effectiveness ratio is reduced to US$54 per life year 
saved.  
 
 
DISCUSSION  
 
Our analysis demonstrates that screening of patients presenting with advanced HIV disease 
for cryptococcal meningitis combined with a short intensive period of adherence support is 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz453/5509363 by U
niversity of Liverpool user on 04 June 2019
  6  
likely to be cost-effective for most settings in Africa [18-20]. The average cost per patient of 
the intervention compares favourably with those of other interventions in Africa such as 
providing outpatient HIV counselling, testing and ART treatment in Nigeria [21], and other 
ART services in Zambia, Kenya, Burkina Faso and South Africa [22-27]. A strength of the trial 
is that it was done in close to normal health service conditions, with for example, 
government employed health care workers managing the patients using national guidelines.  
 
The home-based adherence support component involved the use of trained lay-workers 
visiting the homes of patients by public transport. The cost of home visits – up to about $80 
for most participants - was the major driver of total costs. Trial participants were scattered 
and lay-workers travelled between patient houses. In a small sub-sample, we estimated that 
the lay-workers took about 50-60 minutes to travel from one patient’s house to the next, 
and that this was about twice the amount of time that they actually spent at a patient’s 
home. Further, on some days, particularly near the start of the trial, some lay-workers made 
only one or two home visits a day because we had not recruited sufficient numbers of 
patients. In real life, if this approach was rolled out universally, many patients would be on 
therapy and the increased patient density would reduce travel distances. Health services 
would also identify long-term lower cost ways of travelling between houses, such as field-
workers travelling on bicycles or motorbikes, which were not practical during the normal 
course of trial. The costs could be reduced further by use of alternative methods of 
providing support, such as through mobile phones. If the cost per home visit decreased from 
$19.51 to $5, this will result in an average incremental cost of $33 for the intervention, 
subsequently reducing the average incremental cost effective ratio to $30 per life year 
saved, using a conservative life expectancy of 24 years. If we assume a life expectancy of 35 
years for participants on antiretroviral therapy, the incremental cost-effective ratio 
becomes $20 per life year saved.  
 
In the CrAg screening component, we have over-estimated the cost of CrAg testing. The cost 
of a single test was $5 and a single test was done to identify a single CrAg positive person. 
The CrAg test is simple and its cost will fall with expanded use. Also, the prevalence of CrAg 
positivity was lower in our study than the average reported in Africa [17, 28].  
 
Finally, we calculated cost-effectiveness based on a health care perspective and did not 
assess societal benefits, for example the benefits of increased productivity arising from 
improved health status. We also used a conservative estimate of life expectancy calculated 
taking CD4 count into account. Had we used WHO estimates of life expectancy for Tanzania 
[29], the incremental cost-effectiveness ratio would have been even lower.  
 
Thus, all-in-all, the intervention tested will be highly cost-effective, with a likely incremental 
cost-effectiveness ratio of somewhere between $10-$20 per life year saved. 
 
With complex interventions, as that employed here, it is impossible to disentangle the 
effects of the CrAg individual component from the enhanced adherence component but it is 
very clear that as combined, this is an important new intervention for African HIV services to 
consider for HIV-infected persons with advanced HIV disease. The effects of CrAg screening 
beyond CD4 count of 100 cells / l or more are unknown as there are no other data, besides 
ours, that have tested for CrAg at higher than this CD4 count. Our study found fewer CrAg 
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positive cases in the group that had CD4 counts between 100 and 200 cells / l, and as 
expected, the death rate in this group was lower than in those with lower CD4 counts. This 
lowers the incremental cost-effectiveness ratio.  In our study, the combined intervention 
was as cost-effective at CD4 count <200 cells / l as at CD4 count <100 cells / l, presumably 
because survival is better achieved when we initiate interventions at an earlier disease 
stage. More data are needed of CrAg prevalence above 100 cells / l CD4 count.  
 
Because of the limited evidence around cost-effectiveness, coverage of CrAg screening 
combined with pre-emptive fluconazole has remained low [10], despite being 
recommended by WHO [9]. A study from South Africa had suggested that such an 
intervention is cost-effective [30] but the findings from a middle-income setting are difficult 
to generalise to low-resource settings. In Uganda, a similar cost-effectiveness study, led to 
the same conclusions [31]. Both studies had modelled cost-effectiveness from the health 
care perspective, and have not been enough to facilitate a higher scale up of CrAg screening. 
Our study estimated cost-effectiveness using empirical data from a large cohort in 2 
countries. We calculated costs from the health care pespective and the findings 
demonstrate clearly that this intervention is highly cost-effective even in low-resource 
settings.  
 
For patients who are CrAg positive, mortality is 2-3 times higher even with prompt pre-
emptive treatment with fluconazole and combined with enhanced adherence support than 
that in CrAg negatives [9]. A more potent regimen is needed. A recent large trial 
demonstrated that flucystosine, when added to fluconazole, is a highly effective oral 
combination for the management of patients with confirmed cryptococcal meningitis and 
even at current prices, is highly cost-effective compared with fluconazole monotherapy, 
with an incremental cost-effective ratio of US$65 per life year saved [32]. This oral 
combination needs urgent evaluation of cost-effectiveness in CrAg positive persons.  
Findings from Uganda [33] and South Africa [34] suggest that in asymptomatic persons, the 
CrAg titre predicts mortality, suggesting that the oral combination might only be needed for 
this group. 
The number of persons presenting with advanced disease is likely to remain high for the 
foreseeable future, since alongside the large number of people who still delay accessing ART 
services, there are many dropping out of care or failing on ART. With the findings of this 
analysis and the recent trial of the management of cryptococcal meningitis [5], we can now 
begin to reduce this mortality in cost-effective and sustainable ways.  
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Table 1. Unit Costs (in 2017 US$) and quantity of resources utilised (and standard deviation) 
per study participant in each by arm, over 12 months a. 
 
Cost component 
Unit 
price($)  
Unit of 
measurement 
Intervention 
(n=1001) 
Standard care 
(N=998)  
Outpatients visits     Mean (STD) Mean (STD) 
Initial visits 8.93 Visit 1.05(0.36) 1.04(0.37) 
ART eligibility assessment visit 7.99 Visit 1.16(0.44) 1.10(0.33) 
Six-monthly clinic review visit 8.92 Visit 0.81(0.77) 0.79(0.81) 
Routine follow-up visit 7.62 Visit 3.89(2.77) 3.56(2.81) 
Home visit
b
 19.51 Visit 3.06(1.43) 0.01(0.18) 
Laboratory       
CD4 count test 20.86 Test 1.55(0.62) 1.51(0.62) 
Liver function (ALT) test 1.16 Test 1.27(0.59) 1.19(0.56) 
Creatinine test 0.41 Test 0.89(0.44) 0.87(0.44) 
Haemoglobin (Hb) test 1.15 Test 1.46(0.73) 1.35(0.68) 
Syphilis (VDRL) test 1.13 Test 0.03(0.18) 0.03(0.17) 
Pregnancy test 2.50 Test 0.14(0.47) 0.13(0.44) 
Xpert test 25.23 Test 0.96(0.61) 0.82(0.46) 
CrAg test 5.24 Test 0.98(0.13) 0.01(0.08) 
CSF test 21.55 Test 0.01(0.09) 0.00(0.00) 
Chest X-ray 2.70 X-ray 0.05(0.21) 0.04(0.19) 
Medication     
Days on antiretroviral therapy  0.56 Day 260.47(137.23) 250.27(140.70) 
Days on co-trimoxazole treatment 0.02 Day 263.22(136.00) 254.82(139.76) 
10-week fluconazole course
c
 6.35 Course 0.07(0.37) 0.00(0.00) 
Hospitalisation      
Overnight hospital stay  35.00 Day 0.18(1.17) 0.22(1.55) 
CrAg, cryptococcal antigen; CSF, cerebrospinal fluid; ART, antiretroviral therapy; VDRL, veneral disease 
research laboratory; STD, standard deviation 
a
Unit prices for all tests apart from patients do not include overhead costs 
b
Home visit costs included monthly salary for the lay worker, communication and transport allowance and 
training costs 
c
800 mg per day for 2 weeks and then followed by 400 mg per day for 8 weeks,  200 mg/d thereafter (after 10 
weeks) 
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Table 2: Incremental cost-effectiveness ratios (incremental cost per life year saved) comparing the intervention with standard care according 
to baseline CD4 count 
 
 Life 
expectancy 
(years)
a
, 95% 
CI 
Standard care arm Intervention arm Incremental comparison of the intervention 
versus standard care 
  N Mean total 
cost (US$) per 
person (95% 
CI) 
All-cause mortality N Mean total 
cost (US$) per 
person (95% 
CI) 
All-cause mortality Incremental 
cost (US$) per 
person
b
  
(95% CI) 
Incremental 
death (%)
b
 
(95% CI) 
ICER 
(incremental 
cost per life 
years saved) 
(95% CI) 
    Events 
(95% CI) 
Death rate 
(95% CI) 
  Events  
(95% CI) 
Death rate 
(95% CI)  
   
CD4 <200 cells / l 24.0 998 262 180 18.0 1001 339 134 13.4 77 -4.6 70 
 (22.2 – 25.8)  (254 – 269) (156-203) (15.6-20.3)  (331-347) (113-156) (11.3-15.6) (66-88) (-7.8, -1.3) (43, 211) 
CD4<100 cells / l 18.7 707 262 144 20.2 724 341 114 15.7 79 -4.5 91 
 (17.2 – 20.3)  (253 – 271) (123-165) (17.4-23.3)  (331-350) (94-134) (13.0-18.5) (65-92) (-8.6, -0.6 (49, 443) 
ICER, incremental cost-effectiveness ratio: estimated by dividing incremental cost by the mean number of life years saved (i.e., incremental 
death multiplied by life expectancy).    
aWeighted life expectancy based on a previous study[15] 
bDifferences were estimated using regression equations adjusting for body weight and heamoglobin levels measured at baseline. 
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Figure 1. Cost-effectiveness planes after bootstrapping showing uncertainty in the 
estimated incremental costs and the annual probability of death (%) for persons with CD4 
cell count up to 200 cells / l (red dots) and among persons with CD4 count <100 cells / l 
(blue dots). Ellipses represent 95% confidence intervals and dots represent estimated 
incremental costs and death rates.  
 
   
Figure 2.  Cost-effectiveness acceptability curves showing the probability of cost-
effectiveness at different willingness to pay thresholds according to baseline CD4 count. 
 
 
  Figure 3. Tornado diagram of change in the base-case incremental cost-effectiveness ratio 
among persons with CD4 cell count up to 200 cells / l produced from a deterministic one-
way analysis of six input parameters. The ranges used in the sensitivity analysis were based 
on 95% confidence intervals calculated from the REMSTART data and previous studies.  
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